Stifel Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $3
Benzinga Newsdesk 5 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Stifel analyst James Condulis downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $25 to $3.
Stifel analyst James Condulis downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $25 to $3.